Ruthenium(III) complexes, [RuX(EPh3)2(L)] (X=Cl, Br; E=P, As; L=tridentate Schiff base dianion), have been synthesised by reacting [RuCl3(PPh3)3], [RuCl3(AsPh3)3] or [RuBr3(AsPh3)3] with thiosemicarbazones of methyl- and ethyl acetoacetates. All of the new complexes have been characterised by elemental analyses, IR, electronic, EPR and cyclic voltammetric data and an octahedral structure has been tentatively proposed. The ruthenium(III) complexes were found to be effective catalysts for the oxidation of alcohols to the corresponding carbonyl compounds in the presence of N-methylmorpholine-N-oxide (NMO) as a co-oxidant. The Schiff bases and the new complexes have been tested for the in vitro growth inhibitory activity against the bacteria E. Coli, Bacillus sp. and Pseudomonas sp.
No takes yet. Share an insight, caveat, or question.
Jayabalakrishnan et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: